Join us in Philadelphia this September for the DTRF "Together We Will" Weekend: - Register today!

The Desmoid Tumor Research Foundation

Sara Keller

by

Sara’s journey with the Desmoid Tumor Research Foundation (DTRF) began when she was diagnosed with a desmoid tumor seven years ago. Sara served as the first DTRF marketing intern in 2025 and is currently completing her summer Marketing & Communications Fellowship. With her creative and community-oriented mindset, she is thrilled to further develop her communication skills by working with a Foundation she is deeply connected to.

Sara is a junior at the College of William & Mary in Virginia, where she studies marketing and history. When she is not designing graphics on Canva, she is usually out for a run, nose-deep in a book, or spending time with loved ones.

by

Dr. Elnekave is a consultant interventional radiologist practicing clinically in Israel and the United States. Dr. Elnekave completed his interventional radiology training at Memorial Sloan Kettering Cancer Center in 2012. He served as the director of the Interventional Oncology service at Rabin Medical Center from 2014-2022 and the founding director of the Kahn Unit for interventional Oncology at Share Tzedek Medical Center in Jerusalem in 2022.

Dr Elnekave leads a multidisciplinary team of bioengineers, data scientists and cancer biologists aplying the tools of vascular interventional radiology to the realization of personalized cancer therapy. 

He is an active member of the Society for Interventional Oncology, the Cardiovascular and Interventional Radiological Society of Europe and the EORTC Soft Tissue and Bone Sarcoma Group.

by

Dr. Navid is a Pediatric Oncologist, Professor of Clinical Pediatrics, and Medical Director for Clinical Research for the Cancer and Blood Disease Institute at the Children’s Hospital Los Angeles. Her primary clinical and research interests are in pediatric bone and soft-tissue sarcomas (including desmoid tumors) and early phase drug development for pediatric solid tumors. She is an active member of the Children’s Oncology Group (COG) Soft Tissue Sarcoma and Developmental Therapeutics Committees. Specific to desmoid tumors, Dr. Navid leads the COG phase 2 study of nirogacestat in children and adolescents with unresectable desmoid tumors (ARST1921).

by

Dr. Reineke Schoot is a pediatric oncologist at the Princess Máxima Center in Utrecht, The Netherlands. She is a group leader in drug development for patients with solid tumors, with particular expertise in sarcomas. Dr. Schoot is principal investigator of several clinical trials, including studies with registration intent.

In collaboration with Dr. Michela Casanova of Istituto Tumori Milano, she is leading the development of the OCTOPUS platform trial, a master protocol comprising multiple sub-trials focused on the treatment of pediatric patients with soft tissue sarcoma. This research is conducted within the EpSSG (European paediatric Soft tissue sarcoma Study Group) and the ITCC (Innovative Therapies for Children and adolescents with Cancer) network. One of the first sub-trials within OCTOPUS is dedicated to pediatric patients with desmoid tumors.

by

Dr. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Medical Director (Oncology) of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. Dr. Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology and Sarcoma Medical Oncology. He was elected as a Fellow of ASCO (FASCO) in 2024.

In recent years, Dr. Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

Dr. Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee (IAC) and the Asia-Pacific Regional Council of ASCO. After completing his role as the Chair of the IAC of ASCO (2024-25), He currently serves as the Immediate Past Chair (2025-2026). He has also served in the Membership, Education and Communications Committees of the IASLC. He was selected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. Dr. Loong is a current Steering Committee member of the Lung Cancer Policy Network (LCPN). In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

by

Dr. Dossa is an Assistant Professor of Surgery and Computational Biomedicine at Cedars-Sinai Medical Center. Following completion of her fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center, she completed a post-doctoral fellowship in Sarcoma Surgery at the Istituto Nazionale dei Tumori in Milan, Italy. She has both clinical and academic focuses in the treatment of patients with soft tissue sarcomas, including optimizing patient selection for multimodal treatment strategies and investigating novel data-driven methods to enhance the feasibility of rare cancer research.

Dr. Dossa is a member of the Sarcoma Disease Site Working Group of the Society of Surgical Oncology and co-chair of the Clinical Trials Committee of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).